Your session is about to expire
← Back to Search
P4 Phantom for Glioblastoma
N/A
Waitlist Available
Led By Harrison Kim, PhD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients treated with surgery, followed by chemoradiation therapy, and currently under chemotherapy
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at the end of cycle 2 of chemoradiation therapy (each cycle is 28 days)
Awards & highlights
Study Summary
This trial is testing whether a new device, the P4 phantom, can improve the accuracy of measuring blood flow in brain tumors. This may lead to better prognosis for brain cancer patients.
Who is the study for?
This trial is for adults over 18 with glioblastoma who've had surgery, chemoradiation, and are on chemotherapy. They must have a new or growing lesion after radiation therapy. It's not for those on dialysis, with MRI contraindications, or pregnant/planning pregnancy.Check my eligibility
What is being tested?
The study tests a device called P4 to improve blood flow measurement in brain tumors using DCE-MRI. The aim is to reduce errors across different MRI scanners and over time by using an artificial tissue standard alongside the patient's scan.See study design
What are the potential side effects?
Since this trial involves imaging rather than medication or invasive procedures, there are no direct side effects from the intervention being tested (P4). Standard MRI-related precautions apply.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I had surgery, then chemoradiation, and am now on chemotherapy.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at the end of cycle 2 of chemoradiation therapy (each cycle is 28 days)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at the end of cycle 2 of chemoradiation therapy (each cycle is 28 days)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Glioblastoma
To measure the reproducibility of qDCE-MRI measurement of glioblastoma.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Glioblastoma patientsExperimental Treatment1 Intervention
glioblastoma patients with newly or enlarged enhancing lesion within 3 months after completing 6 weeks of adjuvant chemoradiation therapy
Find a Location
Who is running the clinical trial?
National Center for Advancing Translational Sciences (NCATS)NIH
324 Previous Clinical Trials
401,614 Total Patients Enrolled
1 Trials studying Glioblastoma
50 Patients Enrolled for Glioblastoma
University of Alabama at BirminghamLead Sponsor
1,594 Previous Clinical Trials
2,282,457 Total Patients Enrolled
10 Trials studying Glioblastoma
255 Patients Enrolled for Glioblastoma
Harrison Kim, PhDPrincipal InvestigatorUniversity of Alabama at Birmingham
2 Previous Clinical Trials
105 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I had surgery, then chemoradiation, and am now on chemotherapy.I have a new or larger tumor in the area treated with radiation, three months after treatment.I am 18 years old or older.I am on hemodialysis or have acute kidney failure.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Research Study Groups:
This trial has the following groups:- Group 1: Glioblastoma patients
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Share this study with friends
Copy Link
Messenger